Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
Clinical trial NCT04216589 · COMPLETED
Trial details
- NCT number
- NCT04216589
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-19
- Primary completion
- 2023-03-16
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.